Trial Design:

  • Prospective, multi-center, randomized trial
  • Randomization 2:1 (Ranger DCB vs. Uncoated balloon)
  • 105 patients with femoropopliteal artery lesions
  • 10 sites (Germany, France, and Austria)


Primary endpoint:

  • In-segment late lumen loss of the treated segment, as observed by angiography at six months post-procedure

Secondary endpoints:

  • Restnosis and patency rates
  • Rutherford classification / clinical success
  • Ankle-brachial index / hemodynamic success
  • Quality of life (WIQ, EQ5D, SF12)

Similar lesion characteristics between Ranger and control groups


RangerTM DCB SFA Trial Efficacy and Safety Results

Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.